Patents by Inventor Gordon E. Willick

Gordon E. Willick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6541450
    Abstract: This invention describes analogues of human parathyroid hormone which have increased activities in bone restoration, and increased bioavailability. The peptides described are derivatives of hPTH-(1-31) which are cyclized for example, by formation of lactams between either Glu22 and Lys26 or Lys26 and Asp30. In addition, the natural Lys27 may be substituted by either a Leu or other hydrophobic residues, such as Ile, norleucine, Met, Val, Ala, Trp, or Phe. Typically, these analogues have enhanced abilities to stimulate adenylyl cyclase in rat osteosarcoma cells, and show increased activities in bone restoration, using the ovariectomized rat model. The analogues also show enhanced activities and bioavailabilities, as demonstrated by their hypotensive effects in the rat. An assay which correlates hypotensive activity with osteogenic activity is also described.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: April 1, 2003
    Assignee: National Research Council of Canada
    Inventors: Jean-Rene Barbier, Paul Morley, Witold Neugebauer, James F. Whitfield, Gordon E. Willick
  • Patent number: 6316410
    Abstract: The invention disclosed relates to analogues of human parathyroid hormoneh(PTH) which have increased activities in bone restoration, and increased bioavailablities. The analogues described are either single cyclic (1-28) or (1-29) analogues, or double cyclic (1-28) to (1-31) analogues. The single cyclic analogues are cyclised between amino acid pairs R22 and R26. The double cyclic analogues are cyclised between amino acid pairs 13 and 17, and 22 and 26. Various substitutions of the natural residues for other amino acids are also described. For example, the natural Lys27 residue may be substituted by Leu. Typically, these novel analogues have enhanced abilities to stimulate adenyl cyclase activity in rat osteosarcoma cells, and show increased activities in bone restoration using the ovariectomized rat model.
    Type: Grant
    Filed: September 22, 1999
    Date of Patent: November 13, 2001
    Assignee: National Research Council of Canada
    Inventors: Jean-René Barbier, Paul Morley, James F. Whitfield, Gordon E. Willick
  • Patent number: 6110892
    Abstract: This invention describes analogues of human parathyroid hormone which have increased activities in bone restoration, and increased bioavailabilities. The peptides described are derivatives of hPTH-(1-31) which are cyclized for example, by formation of lactams between either Glu.sup.22 and Lys.sup.26 or Lys.sup.26 and Asp.sup.30. In addition, the natural Lys.sup.27 may be substituted by either a Leu or other hydrophobic residues, such as Ile, norleucine, Met, Val, Ala, Trp, or Phe. Typically, these analogues have enhanced abilities to stimulate adenylyl cyclase in rat osteosarcoma cells, and show increased activities in bone restoration, using the ovariectomized rat model. The analogues also show enhanced activities and bioavailabilities, as demonstrated by their hypotensive effects in the rat. An assay which correlates hypotensive activity with osteogenic activity is also described.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: August 29, 2000
    Assignee: National Research Council of Canada
    Inventors: Jean-Rene Barbier, Paul Morley, Witold Neugebauer, Virginia J. S. Ross, James F. Whitfield, Gordon E. Willick
  • Patent number: 5955425
    Abstract: This invention describes analogs of human parathyroid hormone which have increased activities in bone restoration, and increased bioavailabilities. The peptides described are derivatives of hPTH-(1-31) which have lactams formed for example, between either Glu.sup.22 and Lys.sup.26 or Lys.sup.26 and Asp.sup.30. In addition, the natural Lys.sup.27 may be substituted by either a Leu or other hydrophobic residues, such as Ile, norleucine, Met, Val, Ala, Trp, or Phe. Typically, these analogs have enhanced abilities to stimulate adenylyl cyclase in rat osteosarcoma cells, and show increased activities in bone restoration, using the ovariectomized rat model. The analogs also show enhanced activities and bioavailabilities, as demonstrated by their hypotensive effects in the rat.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: September 21, 1999
    Assignee: National Research Council of Canada
    Inventors: Paul Morley, Witold Neugebauer, Virginia J. S. Ross, James F. Whitfield, Gordon E. Willick, Jean-Rene Barbier
  • Patent number: 5556940
    Abstract: Certain analogues of human parathyroid hormone (hPTH) have been found to be effective for the treatment of osteoporosis, while showing decreased side effects. Analogues showing this effect include all sequences from hPTH-(1-28)-NH.sub.2 to hPTH-(1-31)-NH.sub.2 and all sequences from [Leu.sup.27 ]-hPTH-(1-28)-NH.sub.2 to [Leu.sup.27 ]-hPTH-(1-33)-NH.sub.2. Also included are cyclic analogues cyclo(Lys.sup.26 -Asp.sup.30) [Leu.sup.27 ]-hPTH-(1-34)NH.sub.2 and cyclo (Lys.sup.27 -Asp.sup.30 )-hPTH-(1-34)-NH.sub.2. Analogues in the form of the carboxyl terminal amide are particularly effective.
    Type: Grant
    Filed: June 20, 1994
    Date of Patent: September 17, 1996
    Assignee: National Research Council of Canada
    Inventors: Gordon E. Willick, James F. Whitfield, Witold Surewicz, Wing L. Sung, Witold Neugebauer